The medtech company Vibrosense Dynamics reports decreased revenue and a larger negative result in the sixth quarter of 2025, compared with the same period last year.Net sales amounted to SEK 0.4 million (0.5), corresponding to a decrease of 8.9 percent. Revenue consists of sales and rental of foot and hand instruments.Result after financial items amounted to SEK -1.6 million (-1.0). Earnings per share amounted to SEK -0.05 (-0.04). The result for the latest quarter was burdened by an inventory write-down and the rebooking of accrued patent costs. The equity ratio amounted to 83.6 percent (84.4)."During the sixth and final quarter of 2025, Vibrosense took several steps in its international expansion. With new collaborations and studies in diabetes and oncology, we have continued to strengthen our clinical relevance. We have updated our business model and intensified our marketing and sales efforts in Europe and Asia, which gives us a clearer and more scalable path toward future growth," says CEO Toni Speidel in a comment. He continues. "We are entering 2026 with strong confidence and a promising international pipeline of business opportunities. Although short-term revenue is affected by the delay of the China launch, we see good opportunities to generate growth as our clinical collaborations and marketing efforts begin to bear fruit."